Patent · US Expired

Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances

US6750221B1 · kind B1 · utility

3Cited by

2References

11Claims

0Family size

Assignee

BASF SE

Inventors

Francisco Javier Garcia-Ladona · Kandel, DE
Laszlo Szabo · Ditzingen, DE
Gerd Steiner · Tauberbischofsheim, DE
Hans P. Hofmann · Schifferstadt, DE

Key dates

Filing date	Jul 11, 2001
Grant date	Jun 15, 2004
Priority date	—
Expiry date	Jul 11, 2021

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of binding partners for 5-HT5-receptors in the treatment of neuropathological and in particular neurodegenerative and/or neuropsychiatric disturbances which can occur notably in cases of cerebral ishcemia, cerebral stroke, epilepsy and attacks in general, chronic schizophrenia, other psychotic illnesses, dementia, notably Alzheimer's disease, demyelination diseases, notably multiple sclerosis and brain tumors. The invention also relates to methods, especially screening methods, for identifying and characterizing such binding partners.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.